Guizhou Xinbang Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 002390.SZ

Guizhou Xinbang Pharmaceutical Co., Ltd. Gross Profit for the year ending December 31, 2023: USD 173.04 M

Guizhou Xinbang Pharmaceutical Co., Ltd. Gross Profit is USD 173.04 M for the year ending December 31, 2023, a -1.87% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

Guizhou Xinbang Pharmaceutical Co., Ltd. Gross Profit for the year ending December 31, 2022 was USD 176.35 M, a -17.15% change year over year.
Guizhou Xinbang Pharmaceutical Co., Ltd. Gross Profit for the year ending December 31, 2021 was USD 212.86 M, a 10.97% change year over year.
Guizhou Xinbang Pharmaceutical Co., Ltd. Gross Profit for the year ending December 31, 2020 was USD 191.82 M, a -8.79% change year over year.
Guizhou Xinbang Pharmaceutical Co., Ltd. Gross Profit for the year ending December 31, 2019 was USD 210.30 M, a 0.90% change year over year.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

Shenzhen Stock Exchange: 002390.SZ

Guizhou Xinbang Pharmaceutical Co., Ltd.

CEO	Ms. Lingzhong Kong
IPO Date	April 16, 2010
Location	China
Headquarters	Intersection of Hangtian Avenue and Xint
Employees	5,149
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Drugstores & Retail Pharmacies

Description

Guizhou Xinbang Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of Chinese herbal medicines and biological drugs in China and internationally. It offers cardiovascular and cerebrovascular, digestive system, endocrine, tumor and immune regulation, blood system, rheumatism and rheumatoid, urinary system, antipyretic analgesic, cold medication, gynecological treatment, and anti-infective drugs. The company was founded in 1995 and is headquartered in Guiyang, China.

Key trends

Past 5 years